Accenture has made a strategic investment, through Accenture Ventures, in Earli Inc., a biotechnology company that developed a novel approach to early cancer detection with a synthetic targeting platform that selectively reprograms cancer cells to reveal and destroy themselves.
This investment from Accenture Ventures will support expanding collaborations with global health and pharma companies that can use Earli’s technology to more rapidly and accurately detect and treat cancer.
Based in Redwood City, California, Earli’s mission is to transform cancer into a benign experience by solving one of the most difficult challenges in oncology: reliably distinguishing between healthy and cancerous cells. Earli’s approach uses programmable genetic constructs that react and signal the presence of active cancer cells at an early stage. The synthetic biopsy approach enhances the sensitivity and specificity of cancer detection for an earlier diagnosis, allowing pharmaceutical and biotech companies to create personalized treatments more quickly and often at a lower cost.
Petra Jantzer, Ph.D., a senior managing director and global lead of the Accenture Life Sciences business, said, “Earli’s synthetic biopsy method is a step change in early cancer detection technologies and will offer significant advantages to biopharma companies by improving the precision and efficacy of new treatments and diagnostics, as well as in understanding the mechanisms of cancer progressions.”
“Accenture’s impressive network of biopharma clients will be very impactful for Earli. It is fantastic to have Accenture support our mission to make cancer a benign experience," said Cyriac Roeding, Co-Founder & CEO, Earli Inc.
Terms of the investment were not disclosed.
Sourced from Accenture